Avecho Biotechnology Ltd V.AVE

Primary Symbol: AVEFF

Healthcare Biotechnology

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.

OTCPK:AVEFF - Post by User

Avecho Biotechnology Ltd > Terms

<< Previous

Bullboard Posts

Next >>

Comment by skibum45on Apr 16, 2018 6:09pm

156 Views

Post# 27894031

RE:RE:Terms

That pretty much sums it up John. Fully diluted share count from MD&A is 60.6 mil. The earnout is calculated based on 2.74737x(EBITDA for the year following close-18 mil). My math says, considering the fully diluted share count, that the max of $0.45 earnout is reached with an EBITDA of about $28 mil. .... seems doable to me. I actually bought some more at 0.95 today. Seems worth the 5% downside to me. Regardless, will be good to collect the 0.90 in June, and then just watch with zero risk after that point.

<< Previous

Bullboard Posts

Next >>

Transportation technology stock secures second major contract in a week